



Aerospan[®] (flunisolide) – Product Discontinuation

- On January 26, 2018, the [FDA announced](#) the discontinuation of Mylan's [Aerospan \(flunisolide\)](#) due to business reasons.
 - The discontinuation is not due to product quality, safety or efficacy concerns.
 - Per Mylan, there is very sparse supply in the market.
- Aerospan is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older; and for asthma patients requiring oral corticosteroid therapy, where adding Aerospan may reduce or eliminate the need for oral corticosteroids.
- Other currently available inhaled corticosteroids indicated for the treatment of asthma include beclomethasone dipropionate ([QVAR[®] Redihaler[™]](#)), budesonide ([Pulmicort Flexhaler[™]](#)), ciclesonide ([Alvesco[®]](#)), fluticasone furoate ([Arnuity[™] Ellipta[®] \(fluticasone furoate\)](#)), fluticasone propionate ([ArmonAir[™] RespiClick[®]](#), [Flovent[®] Diskus[®]](#), [Flovent[®] HFA](#)), and mometasone furoate ([Asmanex[®] HFA](#), [Asmanex[®] Twisthaler[®]](#)).
 - Refer to individual drug labels for further indication information.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.